Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAZ 191
说明： Potent DYRK1B inhibitor
化学名： N-[2-Methoxy-4-(4-methyl-1-piperazinyl)phenyl]-4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-pyrimidinamine
纯度： ≥98% (HPLC)
生物活性 for AZ 191
AZ 191 is a potent DYRK1B inhibitor (IC50 values are 17, 88 and 1890 nM for DYRK1B, DYRK1A and DYRK2 respectively). Inhibits DYRK1B-induced Gi phase cell cycle arrest in Panc-1 cells in vitro.
External Portal Information for AZ 191
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of AZ 191 is reviewed on the chemical probes website.
化合物库 for AZ 191
AZ 191 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for AZ 191
| 分子量 | 429.52 |
| 公式 | C24H27N7O |
| 储存 | Store at -20°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 1594092-37-1 |
| PubChem ID | 72716071 |
| InChI Key | ZYVXTMKTGDARKR-UHFFFAOYSA-N |
| Smiles | CN2C=C(C3=CC=NC(NC4=C(OC)C=C(N5CCN(C)CC5)C=C4)=N3)C1=CC=NC=C12 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for AZ 191
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 42.95 | 100 | |
| ethanol | 8.59 | 20 |
制备储备液 for AZ 191
以下数据基于产品分子量 429.52。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.33 mL | 11.64 mL | 23.28 mL |
| 5 mM | 0.47 mL | 2.33 mL | 4.66 mL |
| 10 mM | 0.23 mL | 1.16 mL | 2.33 mL |
| 50 mM | 0.05 mL | 0.23 mL | 0.47 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for AZ 191
参考文献 for AZ 191
参考文献是支持产品生物活性的出版物。
Ashford et al (2014) A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3 beta to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochem.J. 457 43 PMID: 24134204
If you know of a relevant reference for AZ 191, please let us know.
按产品操作查看相关产品
关键词: AZ 191, AZ 191 supplier, AZ191, potent, dyrk1b, dual, specificity, tyrosine, phosphorylation, regulated, kinases, inhibitors, inhibits, DYRK, 5232, Tocris Bioscience
2 篇 AZ 191 的引用文献
引用文献是使用了 Tocris 产品的出版物。 AZ 191 的部分引用包括：
Martin et al (2020) Functional Diversification of SRSF Protein Kinase to Control Ubiquitin-Dependent Neurodevelopmental Signaling. Dev Cell 55 629-647.e7 PMID: 33080171
Blake et al (2019) Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Sci Signal 12 PMID: 31311847
您是否知道使用了 Tocris AZ 191 的优秀论文？ 请告知我们.
AZ 191 的评论
目前没有该产品的评论。 Be the first to review AZ 191 and earn rewards!
Have you used AZ 191?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.